The management of pleural mesothelioma has changed with the demonstration that first-line
checkpoint blockade therapy improves survival. This review covers issues of relevance to …

TPS7112 Background: MPM median OS does not exceed 13 months with pem/CDDP
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …

In this commentary, using existing clinical trial data and FDA approvals we propose that
there is currently a critical need for an appropriate balancing between the financial impact of …

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis.
Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF …

Background Median overall survival (OS) is∼ 1 year with pemetrexed/cisplatin, the standard
front-line treatment for patients with unresectable malignant pleural mesothelioma (MPM); …

Malignant pleural mesothelioma (MPM) is a rare, locally invasive, and highly aggressive
cancer originating from the serosal surface of the pleura. Radical surgery, as a part of …

© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018; 10 (3): 1172-1177 jtd.
amegroups. com (fluorodeoxyglucose) uptake and total glycolytic value measured by PET …

Purpose Preclinical and clinical data have shown promise in using antiangiogenic agents to
treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate …

9004 Background. The RAMES Study (EudraCT Number 2016-001132-36) is a multicenter,
double-blind, randomized phase II trial exploring the efficacy and the safety of the addition of …

Background Malignant pleural mesothelioma is a highly aggressive cancer with poor
prognosis and few treatment options following progression on platinum-containing …